Searched for
WINLEVI
Sun Pharma sees steady FY27 growth, progresses $11.75 bn Organon integration dealSun Pharma anticipates strong growth in the coming years. The company expects a high single-digit increase in its overall sales by FY2027. ...- Sun Pharma most exposed Indian company to Trump's new tariff threat, warns JefferiesIndian drug maker Sun Pharma faces significant exposure to potential US tariffs on medicines. Global brokerage Jefferies warns that while g...
- Glenmark Q3 profit rises 16% on strong India, US performanceGlenmark Pharmaceuticals posted 16% growth in December-quarter profit on strong India formulations demand, improved North America performan...
- Glenmark Pharma shares in focus as Q1 profit slumps 86% YoYGlenmark Pharma reported an 86% YoY drop in Q1FY26 net profit to Rs 46.9 crore, even as revenue stayed flat at Rs 3,264 crore. EBITDA slipp...
- Glenmark, Cosmo get MHRA nod for acne treatment medicationGlenmark Pharmaceuticals and Cosmo Pharmaceuticals have received MHRA approval to market Winlevi, a topical acne treatment for patients age...
- Sun Pharma shares tumble 4% as US court blocks Leqselvi launchSun Pharmaceuticals' shares fell by 3.62% after a US court blocked its launch of Leqselvi until further legal developments or the expiry of...
- Sun Pharma shares in focus ahead of Q2 results todaySun Pharma Share Price: Sun Pharma is set to announce its Q2 FY25 results, with revenue growth expected to be driven by domestic business a...
- Glenmark Q1 Results: Net profit doubles to Rs 340 croreGlenmark Pharma net profit doubled to Rs 340 crore crore in Q1FY25 led by robust sales growth in India and Europe and reduction in finance,...
- Sun Pharma Q1 preview: Weak Taro show, soft US sales to weigh on earningsConsolidated net profit is seen declining 1.4% YoY to Rs 2,033 crore. India’s largest pharmaceutical company by market capitalization is sc...
- Hot Stocks: Brokerages on Bharat Forge and Sun Pharma; JPMorgan see 28% upside in PNBBofA Securities maintained its buy rating on Sun Pharma with a target of Rs 1,000. Flattish llumya trend and the company is waiting for Win...
- Buy Sun Pharmaceutical Industries, target price Rs 1180: JM FinancialSun Pharmaceutical Industries Ltd., incorporated in the year 1993, is a Large Cap company (having a market cap of Rs 254653.42 Crore) opera...
- Buy Sun Pharmaceutical Industries, target price Rs 1130: JM FinancialSun Pharmaceutical Industries Ltd., incorporated in the year 1993, is a Large Cap company (having a market cap of Rs 213972.69 Crore) opera...
- Does Sun Pharma's specialty portfolio hold key to its performance?According to the FY 2022 annual report of Sun Pharma, it is ranked number 1 in terms of prescriptions with an 8.34% market share in India. ...
- Sun Pharma expands tie-up with Cassiopea for acne cream to six countriesAs per the tie-up, the company will receive from Cassiopea the exclusive right to develop and commercialise WINLEVI in Japan, Australia, Ne...
- Better pill! Jefferies gives a double upgrade to Sun Pharma stockSun Pharma performance has been a mixed bag in the near term as the shares dropped 13 per cent in the last month, whereas rose close to 7 p...
- Sun Pharma Q3 Results Preview: Net profit may fall 7%; sales seen rising 8-9%Net sales for the pharma major is seen rising 9.04 per cent YoY to Rs 9,635 crore from Rs 8,836 crore in the same quarter last year. Ebitda...
- Sun Pharma might finally have a prescription for the specialty dreamThe ramp-up in its specialty business over the past year has increasingly turned skeptics into believers. The company has four major produc...
- Most analysts raise target prices on Sun Pharma after strong Q2CLSA, which raised the target price on Sun Pharma the most, said the drug maker's results were above estimates with key geographies perform...
- Sun Pharma gets exclusive right to commercialise Winlevi acne cream in US, CanadaSun Pharma, North America CEO Abhay Gandhi said the expiration of the applicable waiting period under the US Hart-Scott-Rodino Antitrust Im...
- Sun Pharma signs in-licensing deal to sell skincare drug in USAcne, being the most prevalent skin condition in the US, affects up to 50 million Americans annually. The last FDA approval of an acne drug...
Load More
